Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed its Q2 2018 10-Q quarterly report on Aug 2, 2018 for the quarter ended Jun 30, 2018.
Teva Pharmaceutical Industries Ltd Q2 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4.7B, down 18% YoY, driven by U.S. generics price erosion and COPAXONE competition
- Gross margin 43.8% vs 49.9%; operating margin negative 0.3% vs negative 100.3% YoY
- Europe strongest: revenue $1.3B, up 3%, profit $346M, up 58%; North America weakest: revenue $2.3B, down 29%
- Cash and investments $1.9B vs $1.5B; operating cash flow $162M vs $435M; capital investment approximately $0.1B
- Headwinds: FDA Davie observations and valsartan recall, with $41M of recall and inventory reserves
Risk Factors
- No material changes identified: risks incorporated by reference to the December 31, 2017 Form 10-K
- Competitive risk: COPAXONE faces existing and potential additional generic competition
- Regulatory risk: potential liability for patent infringement and increased scrutiny of patent settlements
- Operational risk: execution of the restructuring plan announced in December 2017
- Financial risk: substantial indebtedness may restrict additional borrowing and trigger credit-rating downgrades
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teva Pharmaceutical Industries Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.